Research Areas
Our seven major Therapeutic Areas
Boehringer Ingelheim's successes in research & development continuously strengthen our portfolio of medications and offer patients true therapeutic benefit. Our drug discovery focuses on seven major therapeutic areas: cardiovascular diseases, central nervous system (CNS) diseases, immunology & inflammation, metabolic diseases, oncology, respiratory diseases and virology.
Our key therapeutic areas:
Cardiovascular Diseases
Boehringer Ingelheim has been at the forefront of research and development in cardiovascular diseases for decades. Our current focuses in research & development are:
- atherosclerosis
- chronic heart failure
- hypertension
Drug discovery in cardiovascular diseases is conducted at our research & development site in Ridgefield (USA).
Licensing & Partnering at Boehringer Ingelheim.
Information Pack
Acute Coronary Disease
Hypertension
Thromboembolic Diseases
Central Nervous System (CNS) Diseases
Boehringer Ingelheim's research and development focuses on novel treatment concepts for major central nervous system (CNS) diseases:
- chronic pain disorders
- Hypoactive Sexual Desire Disorder (HSDD)
- migraine
- neurodegeneration (Alzheimer's disease, Parkinson's disease)
Drug discovery in CNS diseases is conducted at our research & development site in Biberach (Germany).
Licensing & Partnering at Boehringer Ingelheim.
Information Pack
Acute Stroke
Major Depressive Disorder
Parkinson's Disease
Restless Legs Syndrome
Immunology & Inflammation
Diseases in immunology and inflammation still face unmet medical need for safer and more efficacious treatments. Boehringer Ingelheim's research and development intends to find better ways to treat following diseases:
- multiple sclerosis
- psoriasis
- rheumatoid arthritis
Drug discovery in immunology & inflammation is conducted at our research & development site in Ridgefield (USA).
Licensing & Partnering at Boehringer Ingelheim.
Metabolic Diseases
Boehringer Ingelheim carries out research and development to find new therapeutic approaches for the treatment of metabolic diseases in following areas:
- diabetes type II
- dyslipidemia
- obesity
Drug discovery in metabolic diseases is conducted at our research & development site in Biberach (Germany).
Licensing & Partnering at Boehringer Ingelheim.
Oncology
Boehringer Ingelheim's Research & Development focus on angiogenesis inhibition, signal transduction and cell-cycle kinase inhibition. Research & development in oncology is committed to discovering improved medicines in the fight against such cancers as:
- solid tumors
- lymphomas/ leukaemias
Drug discovery in oncology is conducted at our research site in Vienna (Austria).
Licensing & Partnering at Boehringer Ingelheim.
Information Pack
Oncology
Respiratory Diseases
Respiratory diseases have long been a major focus area for Boehringer Ingelheim. Our main objective in pulmonary research is to provide improved treatment options for:
- chronic obstructive pulmonary disease (COPD)
- severe asthma
- chronic bronchitis
- idiopathic pulmonary fibrosis
Drug discovery in respiratory diseases is conducted at our research & development site in Biberach (Germany).
Licensing & Partnering at Boehringer Ingelheim.
Information Pack
Chronic Obstructive Pulmonary Disease (COPD)
Virology
Boehringer Ingelheim's research and development strives to find medical solutions for acute and chronic viral diseases, such as:
- human immunodeficiency virus (HIV)
- hepatitis C virus (HCV)
Drug discovery in virology is conducted at our research site in Laval (Canada).
Licensing & Partnering at Boehringer Ingelheim.
Information Pack
HIV/AIDS
